Jun. 13 at 4:49 PM
$ANRO $SLS $RFL $IBRX $DRUG
Got asked what the P2 is for, and realized I should give a little bit of knowledge.
Alto's company statement is basically that drug companies have these blanket drugs for all different types of depression bipolar disorder and schizophrenia Etc.
The CEO was a professor at Stanford, and has the idea that by using biomarkers... eegs, wearables, Etc.. they can tailor make / prescribe drugs based off of a user profile.
Imagine no more: "So your dick doesn't work when you try prozac, and now you're more depressed, let's try Lexapro instead"
Instead 203 act as a fast-acting, dopamine-enhancing agent for reward-deficit syndromes (like anhedonia or treatment-resistant depression), with a cleaner and possibly safer profile than traditional stimulants or emerging psychedelic options.
Without the emotional dulling SSRIs can cause. Its closest comparator is modafinil, but with a mechanism that could allow for more targeted psychiatric application.
